Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.64 EUR
Change Today +0.01 / 1.59%
Volume 0.0
As of 3:22 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - €1.22
52 Week Low
10/13/14 - €0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONY)

oncolytics biotech inc (ONY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONY) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: C$538.0K
Chief Financial Officer
Total Annual Compensation: C$284.2K
Chief Operating Officer and Director
Total Annual Compensation: C$370.5K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: $316.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $143.0K
Compensation as of Fiscal Year 2014.

oncolytics biotech inc (ONY) Key Developments

Oncolytics Biotech Inc. Announces Phase 1 Study in Pediatric Patients with Brain Tumors

Oncolytics Biotech Inc. announced that submission to the U.S. Food and Drug Administration for review, the Investigational New Drug Application containing the protocol titled MC1472: Phase 1 Study of Replication Competent Reovirus (REOLYSIN) in Combination with GM-CSF in Pediatric Patients with Relapsed or Refractory Brain Tumors is now active. The study is an open-label Phase I trial to clarify the safety, and determine possible efficacy, of GM-CSF given prior to administration of intravenous REOLYSIN for children with malignant high grade brain tumors. GM-CSF will be administered on days one and two of each cycle with REOLYSIN administered on days three, four and five. Cycles will be given every 28 days for up to 12 cycles if patients remain without evidence of tumor progression and without intolerable toxicity. The primary outcome for the nine to 18 patients of the Phase 1 study will be safety and tolerability. Secondary goals include median progression free and overall survival in this patient population.

Oncolytics Biotech Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015

Oncolytics Biotech Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $3,608,273, loss before loss taxes of $3,551,838, net loss of $3,551,838, net comprehensive loss of $3,326,247 or $0.04 basic and diluted per share, cash used in operating activities of $2,747,189, acquisition of property and equipment of $11,940 compared to the operating loss of $5,569,588, loss before loss taxes of $5,481,601, net loss of $5,485,451, net comprehensive loss of $5,504,145 or $0.06 basic and diluted per share, cash used in operating activities of $6,164,078, acquisition of property and equipment of $15,980 for the same quarter a year ago.

Oncolytics Biotech Inc. Announces Receipt of Orphan Drug Status from the EMA for Pancreatic Cancer

Oncolytics Biotech Inc. announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. The EMA grants Orphan Designation to medicines intended to treat, prevent or diagnose life threatening and debilitating disease, with a prevalence no greater than five in 10,000 in the EU, and where no satisfactory method of treatment, prevention or diagnosis exists, unless the proposed medicine offers a significant benefit to those with the condition. Following Orphan Designation, sponsors can access a number of incentives including protocol assistance, market exclusivity for a ten-year period following approval and potential fee reductions. The receipt of Orphan Designation does not change the regulatory requirements or process for obtaining marketing approval. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF, and KRAS. Up to 70% of pancreatic cancers have activating Ras pathway mutations and/or over-expressions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONY:GR €0.64 EUR +0.01

ONY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONY.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at